Your browser doesn't support javascript.
Anticoagulation in hospitalized patients with COVID-19.
Baumann Kreuziger, Lisa; Sholzberg, Michelle; Cushman, Mary.
  • Baumann Kreuziger L; Department of Medicine Medical College of Wisconsin, Blood Research Institute, Versiti, Milwaukee, WI.
  • Sholzberg M; Department of Medicine and.
  • Cushman M; Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital, Li Ka Shing Knowledge Institute, University of Toronto, Toronto, ON, Canada; and.
Blood ; 140(8): 809-814, 2022 08 25.
Article in English | MEDLINE | ID: covidwho-2083050
ABSTRACT
Coronavirus disease-19 (COVID-19) includes a thromboinflammatory syndrome that may manifest with microvascular and macrovascular thrombosis. Patients with COVID-19 have a higher incidence of venous thromboembolism than other hospitalized patients. Three randomized control trials suggesting benefit of therapeutic heparin in hospitalized noncritically ill patients with COVID-19 have led to conditional guideline recommendations for this treatment. By contrast, prophylactic-dose heparin is recommended for critically ill patients. Unprecedented collaboration and rapidly funded research have improved care of hospitalized patients with COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Venous Thromboembolism / COVID-19 Type of study: Experimental Studies / Observational study / Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: Blood Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Venous Thromboembolism / COVID-19 Type of study: Experimental Studies / Observational study / Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: Blood Year: 2022 Document Type: Article